Azacitidine.
Jean-Pierre Issa, Hagop M. Kantarjian
Paper details
- Journal
- Nature Reviews Drug Discovery
- Published
- 2005
- Citations
- 0
- Fields
- Medicine
tlooto Summary
Azacitidine (Vidaza; Pharmion), an inhibitor of DNA methylation, was approved by the US FDA for the treatment of myelodysplastic syndromes in May 2004, and has been given orphan-drug status.
Abstract
Azacitidine (Vidaza; Pharmion), an inhibitor of DNA methylation, was approved by the US FDA for the treatment of myelodysplastic syndromes in May 2004. It is the first drug to be approved by the FDA for treating this rare family of bone-marrow disorders, and has been given orphan-drug status. It is also a pioneering example of an agent that targets 'epigenetic' gene silencing, a mechanism that is exploited by cancer cells to inhibit the expression of genes that counteract the malignant phenotype.
Citation format
ISSA, Jean-Pierre; KANTARJIAN, Hagop M. Azacitidine. Nature Reviews Drug Discovery, 2005, Suppl: 6–7.